...are in Phase III trials in the setting: an extended release formulation of nitazoxanide from Romark Laboratories L.C....

...immunocompromised adult mouse models of infection. Next steps include testing AN3661 in larger animal models. Romark Laboratories L.C....
...pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea caused by C. parvum and Giardia lamblia . Romark...

...models of colorectal cancer. Romark Laboratories L.C. markets Alinia, a pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea. Romark...

...Basel, Switzerland) markets Tamiflu under a license from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Romark Laboratories L.C....

...a Phase I trial. BIntercell is testing its vaccine with the small molecule nitazoxanide from Romark Laboratories L.C....

...develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Romark Laboratories L.C....

...Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...

...Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...
...Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Roche markets Pegasys and Copegus. Romark Laboratories L.C....

...to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Roche markets Pegasys and Copegus. Romark Laboratories L.C....

...already marketed in the U.S. to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Romark Laboratories L.C....